Dourish CT - Search Results

1

Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190.

Routledge C, Gurling J, Ashworth-Preece MA, Dourish CT. Routledge C, et al. Among authors: dourish ct. Eur J Pharmacol. 1995 Apr 4;276(3):281-4. doi: 10.1016/0014-2999(95)00082-v. Eur J Pharmacol. 1995. PMID: 7601215

2

In vivo characterization of the putative 5-HT1A receptor antagonist SDZ 216,525 using two models of somatodendritic 5-HT1A receptor function.

Routledge C, Hartley J, Gurling J, Ashworth-Preece M, Brown G, Dourish CT. Routledge C, et al. Among authors: dourish ct. Neuropharmacology. 1994 Mar-Apr;33(3-4):359-66. doi: 10.1016/0028-3908(94)90066-3. Neuropharmacology. 1994. PMID: 7984274

3

Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY100135: an in vivo microdialysis study.

Routledge C, Gurling J, Wright IK, Dourish CT. Routledge C, et al. Among authors: dourish ct. Eur J Pharmacol. 1993 Aug 3;239(1-3):195-202. doi: 10.1016/0014-2999(93)90994-s. Eur J Pharmacol. 1993. PMID: 8223894

4

Effects of the selective 5-HT1A receptor antagonist WAY100135 and its enantiomers on 8-OH-DPAT-induced hyperglycaemia in conscious rats.

Critchley DJ, Middlefell VC, Liddle CW, Foden ND, Dourish CT. Critchley DJ, et al. Among authors: dourish ct. Eur J Pharmacol. 1994 Mar 11;254(1-2):133-9. doi: 10.1016/0014-2999(94)90380-8. Eur J Pharmacol. 1994. PMID: 8206109

5

Inhibition of 8-OH-DPAT-induced elevation of plasma corticotrophin by the 5-HT1A receptor antagonist WAY100635.

Critchley DJ, Childs KJ, Middlefell VC, Dourish CT. Critchley DJ, et al. Among authors: dourish ct. Eur J Pharmacol. 1994 Oct 13;264(1):95-7. doi: 10.1016/0014-2999(94)90642-4. Eur J Pharmacol. 1994. PMID: 7828650

6

Effects of the putative 5-HT1A receptor antagonist NAN-190 on free feeding and on feeding induced by the 5-HT1A receptor agonist 8-OH-DPAT in the rat.

Williams AR, Dourish CT. Williams AR, et al. Among authors: dourish ct. Eur J Pharmacol. 1992 Aug 14;219(1):105-12. doi: 10.1016/0014-2999(92)90586-s. Eur J Pharmacol. 1992. PMID: 1397037

7

The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.

Bickerdike MJ, Marsden CA, Dourish CT, Fletcher A. Bickerdike MJ, et al. Among authors: dourish ct. Eur J Pharmacol. 1994 Dec 27;271(2-3):403-11. doi: 10.1016/0014-2999(94)90800-1. Eur J Pharmacol. 1994. PMID: 7705440

8

Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist.

Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, Jones DE, McLenachan A, Stanhope KJ, Critchley DJ, Childs KJ, Middlefell VC, Lanfumey L, Corradetti R, Laporte AM, Gozlan H, Hamon M, Dourish CT. Fletcher A, et al. Among authors: dourish ct. Behav Brain Res. 1996;73(1-2):337-53. doi: 10.1016/0166-4328(96)00118-0. Behav Brain Res. 1996. PMID: 8788530

9

Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents.

Fletcher A, Cliffe IA, Dourish CT. Fletcher A, et al. Among authors: dourish ct. Trends Pharmacol Sci. 1993 Dec;14(12):41-8. doi: 10.1016/0165-6147(93)90185-m. Trends Pharmacol Sci. 1993. PMID: 8122313 Review.

10

Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety.

Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Shepherd JK, et al. Among authors: dourish ct. Psychopharmacology (Berl). 1994 Sep;116(1):56-64. doi: 10.1007/BF02244871. Psychopharmacology (Berl). 1994. PMID: 7862931

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

169 results

Search Page

Filters